Becker Muscular Dystrophy Market

Market Overview:

The 7 major Becker muscular dystrophy markets reached a value of US$ 848.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,283.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The Becker muscular dystrophy market has been comprehensively analyzed in IMARC's new report titled "Becker Muscular Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Becker muscular dystrophy (BMD) refers to a genetic condition characterized by progressive muscle wasting and weakness. The symptoms of the disease usually appear in late childhood or adolescence, although they can manifest at any age. The main indication associated with this illness is rapid and gradual muscle weakness that affects the hips, pelvic area, thighs, arms, legs, and heart. Various other symptoms commonly seen in individuals suffering from the ailment include difficulty walking, a waddling gait, frequent falls, calf muscle enlargement, cramps, etc. As the disease progresses, patients may further develop contractures (joint stiffness) and respiratory problems. The diagnosis of BMD typically involves a combination of clinical evaluation, family history assessment, and a physical examination. A healthcare provider may also perform genetic testing via DNA sequencing or multiplex ligation-dependent probe amplification to identify mutations or alterations in the genome that might be contributing to the underlying disorder. In some cases, a biopsy will be recommended to examine muscle tissue under a microscope. This helps to reveal specific changes in the muscle fibers that are characteristic of the ailment.

The increasing cases of mutations in the dystrophin gene, which result in the disruption of vital structural and signaling functions within muscle cells, are primarily driving the Becker muscular dystrophy market. In addition to this, the inflating utilization of corticosteroids, such as prednisone and deflazacort, to slow down muscle degeneration and improve strength in patients is also creating a positive outlook for the market. Moreover, the widespread adoption of several assistive devices, like braces, splints, orthotics, etc., since they provide support, maintain joint alignment, and prevent contractures in individuals suffering from BMD, is further bolstering the market growth. Apart from this, the rising application of physical and occupational therapies that aim to enhance functional abilities and promote independence through exercises and stretches is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which involves delivering functional copies of the defective gene directly into the affected cells to restore the production of a full-length dystrophin protein, is expected to drive the Becker muscular dystrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Becker muscular dystrophy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Becker muscular dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Becker muscular dystrophy market in any manner.

Recent Developments:

• In April 2024, Edgewise Therapeutics, Inc. reported favorable two-year topline findings from the ARCH trial. ARCH is an open-label, single-center trial examining the safety, tolerability, influence on muscle damage biomarkers, pharmacokinetics (PK), and functional assessments of sevasemten (EDG-5506) in people with Becker.

Key Highlights:

• Becker muscular dystrophy is an uncommon disease that affects almost exclusively male persons due to X-linked inheritance.
• Becker muscular dystrophy affects 0.1 to 1.8 out of every 10,000 males globally.
• According to the US studies, the prevalence of Becker muscular dystrophy in all age categories was 0.26 per 10,000 males.
• Symptoms appear at an average age of 11 years, with onset ranging from 2 to 21 years.
• The condition was discovered to be more common among non-Hispanic white people than non-Hispanic black people.

Drugs:

Sevasemten (EDG-5506) is a tiny chemical that prevents damage in a variety of uncommon skeletal muscle disorders, including Duchenne and Becker. Sevasemten has a new method of action that selectively reduces harmful mechanical stress produced by the absence of functional dystrophin, allowing a normal, healthy range of muscular contraction.

Givinostat (ITF2357) is a proprietary histone deacetylase (HDAC) inhibitor used to treat Becker muscular dystrophy. It reduces tumor necrosis factor- α and the release of IL-1 -α,-β, and IL-6. This effect is intended to reduce inflammation and muscle loss in patients.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Becker muscular dystrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Becker muscular dystrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Becker muscular dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Becker muscular dystrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Becker muscular dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Becker muscular dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of Becker muscular dystrophy across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of Becker muscular dystrophy by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of Becker muscular dystrophy by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with Becker muscular dystrophy across the seven major markets?
• What is the size of the Becker muscular dystrophy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Becker muscular dystrophy?
• What will be the growth rate of patients across the seven major markets?
   

Becker Muscular Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Becker muscular dystrophy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Becker muscular dystrophy market?
• What are the key regulatory events related to the Becker muscular dystrophy market?
• What is the structure of clinical trial landscape by status related to the Becker muscular dystrophy market?
• What is the structure of clinical trial landscape by phase related to the Becker muscular dystrophy market?
• What is the structure of clinical trial landscape by route of administration related to the Becker muscular dystrophy market?